echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Over half of the special funds for major new drug development have been spent, with a balance of more than 5 billion yuan

    Over half of the special funds for major new drug development have been spent, with a balance of more than 5 billion yuan

    • Last Update: 2014-02-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    2014-02-26 source: on February 22, medical economics Daily, the reporter learned at the "2014 First Academic Conference on clinical trials of drugs" that, by the end of 2013, China's "12th Five Year Plan" period "major new drug creation" science and technology special cost was about 6.5 billion yuan, and there is still a balance of more than 5 billion yuan Among the funds already spent, more than 70 new drugs have been produced; more than 150 large varieties have been transformed, with a direct economic benefit of 80 billion yuan and an indirect benefit of 300 billion yuan Among the 17 major projects approved by the State Council, the comprehensive index of major new drug projects has jumped to the second place As of September 2013, with the support of "major special fund" for new drugs, 52 varieties have obtained 74 new drug certificates (including 33 varieties and 44 certificates obtained in the 11th Five Year Plan), and 36 varieties have independent intellectual property rights, accounting for 69.23% 52 varieties include: 9 chemicals of class 1; 25 chemicals of class 3; 3 chemicals of class 4; 1 biological product of class 1 for treatment; 1 biological product of class 2 for prevention; 1 biological product of class 2 for treatment; 1 Traditional Chinese medicine of class 5; 9 traditional Chinese medicine of class 6; 1 pharmaceutical auxiliary material Among them, a series of products of influenza prevention and control drugs developed in China, such as oseltamivir phosphate capsule as prevention and treatment drugs, as well as the panamivir trihydrate injection for critical patients, are typical Rhubarb, a new Chinese medicine of anti diabetic nephropathy, is about to enter the second phase of clinical practice; recombinant human urokinase, a new biotechnological drug of class I, has obtained new drug certificate and production approval, and has established a production line with an annual output of 40000 liters of fermentation liquid GPCR has been deployed in advance in China At present, more than 20 GPCR targets related to immune system diseases such as C5aR, c3ar, mGluR1, neurodegenerative diseases, asthma, tumor, etc have been targeted, and 20 lead compounds with new structures have been obtained In terms of biological innovation achievements, Hengrui pharmaceutical has established ADC antibody small molecule coupling platform, and the first generation product shr-a1201 has applied for clinical approval The second generation products are undergoing a comprehensive preclinical evaluation The technical system of vaccine supervision has passed the evaluation of the World Health Organization, and the batch issuance and laboratory integration undertaken by CFDA have passed the full marks In China, Sabin polio inactivated vaccine has completed clinical trials and applied for new drug certificate From the analysis of the acceptance of category 1.1 varieties in 2013, China is still in the stage from imitation to combination of imitation and creation with the first and second level innovation Many participants expect the regulatory authorities to encourage high-level generic drugs and guide the improvement of research and development and production level of generic drugs Some experts also clearly pointed out that China is still in the primary stage of new drug research and development, so we must learn from the experience of international new drug research and development to minimize the loss in the process of new drug research and development, and suggested that clinical research institutions establish "biomarkers" as an important observation end point, because the results of animal experiments can not fully predict the clinical results, while patents are obtained or "novel" It does not mean that it is safe and effective (Hu Rui) >
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.